DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI and Provides Corporate Update

Now seeking out license opportunities for SYMJEPI

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts.

The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.

“Given our renewed focus on our core business, we are taking decisive actions that we believe will remove obstacles and improve our ability to drive long-term growth,” said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals. “This represents an important step in DMK’s ongoing transformation journey as we continue to execute against our operating plan and review our existing business relationships to ensure maximal benefit to DMK’s stakeholders and patients.”

About DMK Pharmaceuticals

DMK Pharmaceuticals is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. DMK’s commercial products approved by the FDA include ZIMHI (naloxone) Injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. DMK believes its technologies are at the forefront of endorphin-inspired drug design with its mono, bi- and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. DMK has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline that could address unmet medical needs by taking the novel approach to integrate with the body’s own efforts to regain balance of disrupted physiology. The Company’s lead clinical stage product candidate, DPI-125, is being studied as a potential novel treatment for OUD. DMK also plans to develop the compound for the treatment of moderate to severe pain. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease. For additional information about DMK Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn.